360 related articles for article (PubMed ID: 10430063)
1. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
Ingle JN; Suman VJ; Johnson PA; Krook JE; Mailliard JA; Wheeler RH; Loprinzi CL; Perez EA; Jordan VC; Dowsett M
Clin Cancer Res; 1999 Jul; 5(7):1642-9. PubMed ID: 10430063
[TBL] [Abstract][Full Text] [Related]
2. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
Dowsett M; Pfister C; Johnston SR; Miles DW; Houston SJ; Verbeek JA; Gundacker H; Sioufi A; Smith IE
Clin Cancer Res; 1999 Sep; 5(9):2338-43. PubMed ID: 10499602
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
4. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
Park IH; Ro J; Lee KS; Kim EA; Kwon Y; Nam BH; Jung SY; Lee S; Kim SW; Kang HS
J Clin Oncol; 2010 Jun; 28(16):2705-11. PubMed ID: 20421538
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial.
Dowsett M; Cuzick J; Howell A; Jackson I;
Br J Cancer; 2001 Aug; 85(3):317-24. PubMed ID: 11487258
[TBL] [Abstract][Full Text] [Related]
7. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
8. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
Mouridsen H; Chaudri-Ross HA
Oncologist; 2004; 9(5):497-506. PubMed ID: 15477634
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
Muss HB; Tu D; Ingle JN; Martino S; Robert NJ; Pater JL; Whelan TJ; Palmer MJ; Piccart MJ; Shepherd LE; Pritchard KI; He Z; Goss PE
J Clin Oncol; 2008 Apr; 26(12):1956-64. PubMed ID: 18332474
[TBL] [Abstract][Full Text] [Related]
11. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of letrozole for advanced breast cancer in postmenopausal patients.
Ansari TN; Mahmood A; Hussain I; Samad A
J Coll Physicians Surg Pak; 2005 Apr; 15(4):204-6. PubMed ID: 15857590
[TBL] [Abstract][Full Text] [Related]
13. Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer.
Rossi E; Morabito A; De Maio E; Di Rella F; Esposito G; Gravina A; Labonia V; Landi G; Nuzzo F; Pacilio C; Piccirillo MC; D'Aiuto G; D'Aiuto M; Rinaldo M; Botti G; Gallo C; Perrone F; de Matteis A
J Clin Oncol; 2008 Jan; 26(2):264-70. PubMed ID: 18086795
[TBL] [Abstract][Full Text] [Related]
14. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
[TBL] [Abstract][Full Text] [Related]
15. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
16. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
[TBL] [Abstract][Full Text] [Related]
17. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
[TBL] [Abstract][Full Text] [Related]
18. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
19. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.
Mouridsen H; Sun Y; Gershanovich M; Perez-Carrion R; Becquart D; Chaudri-Ross HA; Lang R
Oncologist; 2004; 9(5):489-96. PubMed ID: 15477633
[TBL] [Abstract][Full Text] [Related]
20. A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women.
Cigler T; Tu D; Yaffe MJ; Findlay B; Verma S; Johnston D; Richardson H; Hu H; Qi S; Goss PE
Breast Cancer Res Treat; 2010 Apr; 120(2):427-35. PubMed ID: 19967558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]